Prosight Management, LP Alnylam Pharmaceuticals, Inc. Call Options Transaction History
Prosight Management, LP
- $281 Million
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding ALNY
# of Institutions
745Shares Held
111MCall Options Held
916KPut Options Held
841K-
Capital World Investors Los Angeles, CA16.8MShares$7.22 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$5.72 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.1 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.09 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.9 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $52.9B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...